Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JANUARY 2007. Refer to TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | cetuximab (Erbitux®) | |
| Formulation | 5 mg/ml solution for infusion | |
| Reference number | 81 | |
| Indication | Treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer in combination with irinotecan after failure of irinotecan including cytotoxic therapy |
|
| Company | Merck Serono Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Full | |
| Status | Superseded | |
| AWMSG meeting date | 02/03/2006 | |
| Ratification by Welsh Government | 14/06/2006 | |
| Date of issue | 15/06/2006 | |
| NICE guidance | TA118: Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer |
|